Anaptysbio (ANAB) Short-term Investments (2017 - 2026)

Anaptysbio (ANAB) has 10 years of Short-term Investments data on file, last reported at $38.0 million in Q1 2026.

• Quarterly Short-term Investments fell 84.26% year-over-year to $38.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.0 million (down 84.26% YoY) and the FY2025 annual result came in at $73.4 million, down 72.0% from the prior year.
• Short-term Investments slipped to $38.0 million in Q1 2026, from $73.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $394.3 million in Q2 2023 to a low of $38.0 million in Q1 2026.
• A 5-year average of $278.3 million and a median of $301.0 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 640598.33% — and 2026, when it slumped 84.26%.
• Tracing ANAB's Short-term Investments over 5 years: stood at $369.9 million in 2022, then fell by 4.05% to $354.9 million in 2023, then dropped by 26.1% to $262.3 million in 2024, then plunged by 72.0% to $73.4 million in 2025, then tumbled by 48.28% to $38.0 million in 2026.
• The last three Short-term Investments figures came in at $38.0 million (Q1 2026), $73.4 million (Q4 2025), and $139.1 million (Q3 2025), per Business Quant data.